CVS specialty goes retail

Share this article:
CVS specialty goes retail
CVS specialty goes retail

National drugstore chain and PBM CVS Caremark is bringing its specialty prescription business to its retail stores. The company announced the initiative, which is a broader use of its Specialty Connect service, Wednesday. The company said in a statement that this reinvention means patients will be able to treat specialty medications like other run-of-the-mill prescriptions by just walking into one of its 7,600 retail shops. Patients will also be able to tap into a 24/7 phone support team, if needed.

The additional reach will complement the 11 specialty mail-order pharmacies and 25 retail specialty pharmacy stores the company had in its network as of December 2013.

CVS says around 25% of patients who need to fill specialty prescriptions usually have difficulty doing so, which helps trigger a series of consequences including delayed or abandoned treatment.

This ease-of-access component of the strategy also makes good business sense: A review by the IMS Institute for Healthcare Informatics showed that specialty medications have grown an average of 10% in the US every year over the past five years and accounted for around 29% of prescription medication spending last year, up from 23% in 2008.

The category's pull is such that medications for just three categories—MS, autoimmune and oncology—were $6.9 billion, or 68% of last year's total growth, according to IMS, which also found that last year's total spend on new specialty medications came to $7.5 billion in the US.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...